5 Jefferies Group Halozyme Therapeutics Trades
Jefferies Group's position in Halozyme Therapeutics is currently worth $808 Thousand. That's 0.02% of their equity portfolio (589th largest holding). The first Halozyme Therapeutics trade was made in Q2 2023. Since then Jefferies Group bought shares two more times and sold shares on two occasions. The stake costed the investor $711 Thousand, netting the investor a gain of 14% so far.
News about Halozyme Therapeutics Inc. and Jefferies Group
Neuberger Berman Group LLC Decreases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Neuberger Berman Group LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) by 24.6% in the fourth quarter, according...
Genentech''s Subcutaneous Formulation Of Tecentriq Shows Positive Results In Phase III Study
(RTTNews) - Roche''s Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq or atezolizumab with Halozyme''s ENHANZE technology met its...
Goldman Sachs Group Inc. Has $88.41 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Goldman Sachs Group Inc. decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 24.1% in the second quarter, according to the compa...